Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 14, 2024 11:08am
86 Views
Post# 35932688

RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

In the latest letter to US Commerce Secretary and Defense Secretary, lawmakers said the firms are together becoming an industry giant that threatens US intellectual property and national security.

While WuXi AppTec said its business won’t pose security risks to any country, both stocks have suffered an intense selloff since last month. The Shanghai-based pharmaceuticals company said in a filing Tuesday that it has passed US government reviews in the past and “has always welcomed regulatory oversight,” adding the allegations by the lawmakers are inaccurate and misleading.

[ Interestingly WuXiAppTec has used the same argument that the CEO of TicToc had used in defending its footprint in the United Statres ]


https://www.bnnbloomberg.ca/wuxi-apptec-wuxi-bio-slump-as-us-lawmakers-seek-formal-probe-1.2034555


<< Previous
Bullboard Posts
Next >>